Webinars

In oncology clinical trials, a treatment’s fate often hinges on a single question: did the tumor shrink? Standardized frameworks like RECIST and RANO were built to answer that question consistently. Blinded Independent Central Review (BICR) adds a further safeguard, with two independent radiologists reading the same images …

MRI-based response criteria have been widely used in glioma clinical trials over the past decade. However, anatomical MRI is often limited by ambiguity in tumor extent, including non-enhancing disease. It can also be difficult to distinguish post-treatment effects such as pseudoprogression or radionecrosis from true tumor progression. In addition, standard MRI protocols do not capture metabolic tumor activity, limiting insight into underlying tumor biology…

The updated RANO 2.0 criteria from the Response Assessment in Neuro-Oncology (RANO) group introduce refined guidelines for assessing central nervous system (CNS) tumors, particularly gliomas. These updates are crucial for clinical trials, influencing imaging-based endpoints and data collection strategies. In this webinar, MERIT will explore the principles and recommendations of RANO 2.0, focusing on its impact on clinical trial design, imaging assessments, and electronic case report form (eCRF) data collection to ensure accurate response evaluation.

Background & challenge:
In retrospective imaging studies, sites are typically responsible for manually anonymizing images before transfer, causing delays of up to two weeks per request. This can prolong the data collection timeline and introduce inconsistencies in de-identification across sites. This also produces regulatory risk and an increased burden on clinical sites.
 
Solution:
Implementing an automated PHI de-identification module integrated within the imaging platform allows for real-time removal of protected health information (PHI) while preserving essential imaging metadata.

Maintaining consistency and data integrity in imaging assessment can be very challenging in studies with imaging outcomes. There are various sources of variability in imaging assessment, particularly when qualitative assessment is involved in the reading process. In this MERIT webinar, we discuss assessor variability and using reader monitoring plans to mitigate data variability in oncology clinical trials with imaging outcomes such as RECIST 1.1, RANO and other response criteria.

This presentation will give the audience an overview of the role a reading center plays in the use of Optical Coherence Tomography (OCT) in major studies for patients with neovascular Age-related Macular Degeneration (nAMD).

Most brain cancer diagnoses in the United States are glioma, and our upcoming webinar will explore the challenges and potential solutions for assessing these tumors.

Webinar key points: AI Market Space Overview, How to Choose an AI Solution that Best Fits Your Clinical Practice, Challenges and Opportunities of AI Integration in Radiology Clinical Practice

This will be an interactive Q/A style session discussing how early phase centralized image storage can help you secure funding.

 Learn about the fundamentals of Lugano Classification, data collection, and recent academia and industry recommendations on challenges of assessment.

Prostate cancer is one of the most common cancer types in men. With bone as a frequent metastatic site, response assessments for prostate cancer have additional considerations beyond RECIST 1.1.

iRECIST provides guidance for solid tumor response criteria in immunotherapy to accommodate possible pseudoprogression, which may occur in some subjects. In this presentation, MERIT will discuss the rules and principles of iRECIST, imaging endpoints, and special considerations for using iRECIST response criteria.

Does your oncology clinical trial have an imaging component? Are you new to working with imaging core labs? An imaging core lab can provide your team with resources, knowledge, and experience that can help make your study a success.

The Response Assessment in Neuro-Oncology (RANO) group provides various central nervous system-related tumor response criteria and guidance for assessments. In this webinar, MERIT will discuss the principles and recommendations of RANO response criteria for high grade glioma (HGG) and the imaging endpoint information that needs to be collected for clinical trials.

RECIST 1.1 is the standard response criteria for solid tumors and has been a basis for adaptation and variation of other response criteria such as mRECIST, irRECIST, iRECIST, and so on. In this on-demand webinar recording, MERIT discusses the principles of RECIST 1.1, the information needed to collect imaging endpoints, and special considerations while using the RECIST 1.1 criteria.